Bryce E. Riegel, Ph.D.

Bryce Riegel is a patent agent and member of the firm’s Chemistry and Life Sciences Team.  Bryce works closely with chemical, biotechnology, and pharmaceutical clients to facilitate application drafting, patent prosecution, and IP portfolio management, with an emphasis on:

• CNS pharmaceuticals
• Therapeutic antibodies
• Liposomal pharmaceuticals
• Metabolic and GI pharmaceuticals
• Psychedelic-derived pharmaceuticals and their crystalline forms
• Enzymatic production of rare sugars.

Education:

• Georgetown University, Ph.D. 2020
• University of Tulsa, B.S. Biochemistry 2014

Bar Admissions:

• Registered to practice before the U.S. Patent and Trademark Office

Prior Experience

Bryce Riegel earned his Ph.D. from Georgetown University, where his research investigated mechanisms of drug resistance in malaria parasites.

Publications and Presentations

• Altered Drug Transport by Plasmodium falciparum Chloroquine Resistance Transporter Isoforms Harboring Mutations Associated with Piperaquine Resistance.Riegel B, Roepe PD. Biochemistry. 2020 Jul 14;59(27):2484-2493. doi: 10.1021/acs.biochem.0c00247.
• An ortholog of Plasmodium falciparum chloroquine resistance transporter (PfCRT) plays a key role in maintaining the integrity of the endolysosomal system in Toxoplasma gondii to facilitate host invasion. Thornton LB, Teehan P, Floyd K, Cochrane C, Bergmann A, Riegel B, Stasic AJ, Di Cristina M, Moreno SNJ, Roepe PD, Dou Z. PLoS Pathog. 2019 Jun 6;15(6):e1007775. doi: 10.1371/journal.ppat.1007775.
• Analysis of Plasmodium vivax Chloroquine Resistance Transporter Mutant Isoforms. Hassett MR, Riegel BE, Callaghan PS, Roepe PD. Biochemistry. 2017 Oct 17;56(41):5615-5622. doi: 10.1021/acs.biochem.7b00749.
• Heterologous Expression, Purification, and Functional Analysis of Plasmodium falciparum Phosphatidylinositol 3′-Kinase. Hassett MR, Sternberg AR, Riegel BE, Thomas CJ, Roepe PD. Biochemistry. 2017 Aug 22;56(33):4335-4345. doi: 10.1021/acs.biochem.7b00416.